This case illustrates key challenges in managing chronic fungal meningitis in an immunocompetent host, including the limitations of culture-based diagnostics, the difficulty of determining optimal therapy duration, and the clinical decision-making required to initiate empiric therapy in the absence of definitive microbiologic confirmation. The patient’s decade-long course highlights the evolution of available diagnostics and therapeutics, with newer triazoles such as isavuconazole demonstrating improved safety compared to older agents like voriconazole and amphotericin B. These advances lower the threshold for empiric antifungal therapy, underscoring the value of a clinician’s judgment in guiding treatment decisions.